ArticleMammalian genome : official journal of the International Mammalian Genome Society2019
Model validity for preclinical studies in precision medicine: precisely how precise do we need to be?
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- A mouse model of autosomal dominant spastic ataxia and myopathy caused by a mutation in Tuba4a.Human molecular genetics · 2026Article
- Current Animal Models of Cleft Lip and/or Palate: A Narrative Review.Biomedicines · 2026Review
- A mouse model of autosomal dominant spastic ataxia and myopathy caused by a mutation inbioRxiv : the preprint server for biology · 2026Article
- Role of Copper Homeostasis and Cuproptosis in Cardiovascular Disease: Molecular Insights and Metabolic Perspectives.International journal of biological sciences · 2026Review
- The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.BMC cancer · 2025Article
- Personalized and genetically engineered animal models for next-generation surgical implant validation.Annals of medicine and surgery (2012) · 2025Review
- Establishment of a second-generation transgenic marmoset with germline transmission that models polyglutamine disease.Disease models & mechanisms · 2025Article
- Genetic Deletion of Sarm1 in Mouse Models of Three Neurological Diseases.Journal of the peripheral nervous system : JPNS · 2025Article
- SARM1 Inhibition in Three Mouse Models of Charcot-Marie-Tooth Disease.Journal of the peripheral nervous system : JPNS · 2025Article
- Lurcher Mouse as a Model of Cerebellar Syndromes.Cerebellum (London, England) · 2025Review
- Girdin deficiency causes developmental and epileptic encephalopathy with hippocampal sclerosis and interneuronopathy.Epilepsia · 2025Article
- Developmental mechanisms underlying pediatric epilepsy.Frontiers in neurology · 2025Review
- Neurodevelopmental impairment associated with neonatal invasive group BBrain, behavior, & immunity - health · 2024Article
- Improving the predictive power of mouse models.Nature biotechnology · 2024Article
- Roadblocks confronting widespread dissemination and deployment of Organs on Chips.Nature communications · 2024Review
- Mechanisms linking neurological disorders with reproductive endocrine dysfunction: Insights from epilepsy research.Frontiers in neuroendocrinology · 2023Review
- Unravelling inclusion body myositis using a patient-derived fibroblast model.Journal of cachexia, sarcopenia and muscle · 2023Article
- The 12 Rs Framework as a Comprehensive, Unifying Construct for Principles Guiding Animal Research Ethics.Animals : an open access journal from MDPI · 2023Review
- Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Recessive aminoacyl-tRNA synthetase disorders: lessons learned fromFrontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The promise of personalized medicine is that each patient's treatment can be optimally tailored to their disease. In turn, their disease, as well as their response to the treatment, is determined by their genetic makeup and the "environment," which relates to their general health, medical history, personal habits, and surroundings. Developing such optimized treatment strategies is an admirable goal and success stories include examples such as switching chemotherapy agents based on a patient's tumor genotype. However, it remains a challenge to apply precision medicine to diseases for which there is no known effective treatment. Such diseases require additional research, often using experimentally tractable models. Presumably, models that recapitulate as much of the human pathophysiology as possible will be the most predictive. Here we will discuss the considerations behind such "precision models." What sort of precision is required and under what circumstances? How can the predictive validity of such models be improved? Ultimately, there is no perfect model, but our continually improving ability to genetically engineer a variety of systems allows the generation of more and more precise models. Furthermore, our steadily increasing awareness of risk alleles, genetic background effects, multifactorial disease processes, and gene by environment interactions also allows increasingly sophisticated models that better reproduce patients' conditions. In those cases where the research has progressed sufficiently far, results from these models appear to often be translating to effective treatments for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.